Qurient

At a glance

Qurient filed 74 disclosures in the last 12 months, including 17 insider, 8 5% holder and 2 issuance. The most recent key filing was on Sep 4.

Revenue for 2025 was ₩7B, down 23.9% on 2024. It made an operating loss of ₩29.8B. Debt was 58% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3.9B and operating loss of ₩20.5B.

The 2025 annual report lists 32 employees with an average tenure of 5.1 years and average pay of ₩141.8M. Its 8 directors and auditors were paid ₩147M each on average. It paid no cash dividend for 2025. (주)동구바이오제약 and related parties held 10.82% at year end.

From the 2025 annual report

Staff: 32 (12 men, 20 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩4.5B. Directors and auditors: 8, paid ₩1.2B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)동구바이오제약 holds 10.82%; with 0 related parties the group holds 10.82% of common shares at year end (from 7.98% at the start of the year).

Auditor: 우리회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary